Immune function in patients with/β thalassaemia receiving the orally active iron-chelating agent deferiprone

British Journal of Haematology

Volumn 98, Issue 3, 1997, Pages 597-600

  Loebstein, Ronen ^a   Dalal, Ilan ^a   Nisbet Brown, Eric ^a   Berkovitch, Matitiahu ^a   Meydan, Naftaly ^a   Andrews, David ^a   Loubser, Michael D ^a   Koren, Gideon ^a   Roifman, Chaim M ^a   Olivieri, Nancy F ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Deferiprone; Desferrioxamine; Immune function; Thalassaemia

Indexed keywords

CHELATING AGENT; DEFERIPRONE; DEFEROXAMINE;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; BETA THALASSEMIA; CHILD; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNE FUNCTION TEST; IRON CHELATION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 9844262269     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.2463064.x     Document Type: Article

References (12)

1. Agarwal, M.B., Gupte, S.S., Viswanathan, C., Vasandani, D., Ramanathan, J., Desai, N., Puniyani, R.R. & Chablani, A.T. (1993) Deaths in patients receiving oral iron chelator 1,1. (Letter). British Journal of Haematology, 85, 430.
2. Berdoukas, V.A., Bentley, P., Frost, H. & Schnebli, H.P. (1993) Toxicity of oral iron chelator L1. (letter). Lancet, 341, 1088.
3. Boyum, A. (1968) Separation of leukocytes from blood and bone marrow: introduction. Scandinavian Journal of Clinical and Laboratory Investigation, 21, (Suppl. 97), 7.
4. Dwyer, J., Wood, C., McNamara, J., Williams, A., Andiman, W., Rink, L., O'Connor, T. & Pearson, H. (1987) Abnormalities in the immune system of children with beta-thalassaemia major. Clinical and Experimental Immunology, 68, 621-629.
5. Grady, R.W. Akbar, A.N., De Sousa, M., Giardina, P.J. & Hilgartner, M.W. (1988) Transfusion-related immunologic abnormalities in beta-thalassaemia major. Birth Defects, 23, 587-593.
6. Kapadia, A., De Sousa, M., Markenson, A.L., Miller, D.R., Good, R.A. & Gupta, S. (1980) Lymphoid cell sets and serum immunoglobulins in patients with thalassaemia intermedia: relationship to serum iron and splenectomy. British Journal of Haematology, 45, 405-416.
7. Mehta, J., Singhal, S., Chablani, A., Revankar, R. & Walvalker, A. (1991a) L1-induced systemic lupus erythematosus. Indian Journal of Hematology and Blood Transfusion, 9, 33-37.
8. Mehta, J., Singhal, S. & Mehta, B.C. (1993) Deaths in patients receiving oral iron chelator L1. (Letter). British Journal of Haematology, 85, 430.
9. Mehta, J., Singhal, S., Revankar, R., Walvalkar, A., Chablani, A. & Mehta, B.C. (1991b) Fatal systemic lupus erythematosus in patient taking oral iron chelator L1. (Letter). Lancet, 337, 298.
10. Olivieri, N.F. & Brittenham, G.M. (1997) Iron-chelating therapy and the treatment of thalassemia. Blood, 89, 739-761.
11. Pattanapanyasat, K., Webster, H.K., Tungtawe, P., Kongcharoen, P. & Hider, R.C. (1992) Effect of orally active hydroxypyridinone iron chelators on human lymphocyte function. British Journal of Haematology, 82, 13-19.
12. Rose, N., Conway de Macario, E., Fahey, J., Friedman, H. & Penn, G. (eds) (1992) Manual of Clinical Laboratory Immunology. 4th edn. American Society for Microbiology, Washington, DC.